Clinical Trials Logo
  1. Home
  2. Chronic Myeloid Leukemia
  3. NCT00644878

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib — MACS0254  

Chronic Myelogenous Leukemia - Chronic Phase Clinical Trial

Official title:
A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib

Clinical Trial Summary

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00644878
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 2
Start date October 2008
Completion date March 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06082804 - Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia N/A
Recruiting NCT05384587 - Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia Phase 2
Active, not recruiting NCT04666259 - Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Phase 3
Completed NCT04925141 - A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Phase 4
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A
Recruiting NCT03842696 - Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 1/Phase 2